AREDS in Rhode Island

In 2001 and 2013, the National Eye Institute conducted two studies on age-related eye diseases. These studies, called AREDS and AREDS2, found that high doses of certain antioxidants and zinc showed positive effects in the treatment of moderate to severe age-related macular degeneration (AMD). Special vitamins, named AREDS and AREDS2 after the studies, were formulated based on these results and are the only supplements available that have been shown to slow the progression of AMD.

At Koch Eye Associates, our goal is always to improve our patients' quality of life through better vision and eye health using the most effective and cutting-edge treatments available. Patients who have or suspect they have AMD should schedule an exam at one of our facilities in Johnston, North Kingstown, Wakefield, Warwick, or Woonsocket, RI. If you are diagnosed with AMD after your comprehensive exam, we may recommend one of the AREDS formulas for your daily use.

The best candidates for treatment with AREDS or AREDS2 supplements are patients at risk for AMD or who have already been diagnosed with AMD. During your visit to Koch Eye Associates, we will perform a comprehensive evaluation of your overall eye health, your risk for developing AMD, and your lifestyle to determine your candidacy. If you have already been diagnosed with AMD, the evaluation will include the stage of your disease. AREDS is not recommended for patients who smoke or who have smoked in the past, but AREDS2 may be an option. Your ophthalmologist will discuss all of these factors with you during your consultation.

While there is no known prevention or cure for AMD, the advanced stages of the disease can be slowed significantly, meaning some vision can be preserved. The most important factor in maintaining vision with AMD is diligent, consistent treatment. The ophthalmologists at Koch Eye Associates can create a personalized treatment and management plan for your AMD that may include the use of AREDS or AREDS2. Contact one of our Rhode Island offices today to take a stand against age-related macular degeneration.